Publications by authors named "Sabatier R"
Purpose: To compare the clinical outcomes of two different schedules of modern image-guided adaptive brachytherapy (IGABT) in patients underwent chemoradiotherapy (CCRT) and high-dose rate (HDR) brachytherapy (BT) for locally advanced cervical cancer treated (LACC) METHODS AND MATERIALS: Data from medical records of all consecutive patients with histologically proven cervical cancer (FIGO 2018 stage IB-IVA) treated by HDR-BT after CCRT at our institution between 2016 and 2021 were reviewed.
Results: Two hundred and 8 patients with LACC FIGO 2018 stages (IB 20.7%; II 26.
Background: The MOVIE phase I/II trial (NCT03518606) evaluated the safety and antitumor activity of durvalumab and tremelimumab combined with metronomic oral vinorelbine in patients with advanced tumors. We present the results of the recurrent advanced cervical cancer cohort.
Methods: Patients received tremelimumab (intravenously, 75 mg, every four weeks (Q4W); four cycles max) plus durvalumab (intravenously, 1,500 mg, Q4W; 26 cycles max) and metronomic oral vinorelbine (40 mg, every three weeks (3QW)) until disease progression.
Background: In PAOLA-1/ENGOT-ov25, the addition of olaparib to bevacizumab maintenance improved overall survival in patients with newly diagnosed advanced ovarian cancer. We describe the safety profile and quality of life (QoL) of this combination in older patients in PAOLA-1.
Methods: Safety (CTCAE v4.
Antibody-drug conjugates targeting folate receptor alpha (FRα) are a promising treatment for platinum-resistant ovarian cancer (OC) with high FRα expression. Challenges persist in accurately assessing FRα expression levels. Our study aimed to better elucidate FRα gene expression and identify mRNA signatures in OC.
View Article and Find Full Text PDFOvarian cancer (OC) is one of the most common cancers in women, with a high mortality rate. Most of published studies have been focused on Caucasian populations, with the need to explore biological features and clinical outcomes of patients from other ethnicities. We described clinical outcome (progression-free survival and overall survival) and biomarkers associated with survival in a cohort of patients with OC from Tunisia.
View Article and Find Full Text PDFObjective: Treatment of high-grade serous ovarian carcinomas relies on surgery and chemotherapy, potentially followed by bevacizumab and/or poly (ADP-ribose) polymerase inhibitors (PARPi). The modeled CA-125 ELIMination rate constant K (KELIM) is a pragmatic indicator of tumor primary chemosensitivity. Although it is well established that mutations are associated with platinum sensitivity, the relationship between status and KELIM score has yet to be elucidated.
View Article and Find Full Text PDFArticle Synopsis
- The study evaluated the CardioMEMS™ HF System in 103 French patients to assess its feasibility, safety, and clinical benefits post-implantation.
- Over two years, no device-related complications were reported, and the system showed a 50% reduction in heart failure hospitalizations compared to the year before implantation.
- Additionally, patients experienced lower pulmonary artery pressures and improvements in their functional class and overall quality of life.
Purpose: To evaluate atezolizumab combined with platinum-based chemotherapy (CT) followed by maintenance niraparib for late-relapsing recurrent ovarian cancer.
Methods: The multicenter placebo-controlled double-blind randomized phase III ENGOT-OV41/GEICO 69-O/ANITA trial (ClinicalTrials.gov identifier: NCT03598270) enrolled patients with measurable high-grade serous, endometrioid, or undifferentiated recurrent ovarian cancer who had received one or two previous CT lines (most recent including platinum) and had a treatment-free interval since last platinum (TFIp) of >6 months.
Article Synopsis
- - Ovarian cancer is a major cause of death among gynecological cancers, and platinum-based chemotherapy is the primary treatment method, along with maintenance strategies to extend chemotherapy intervals.
- - Current maintenance treatments include bevacizumab and poly ADP-ribose polymerase inhibitors, but these can only be used once during the disease's progression, leaving a gap in treatment for patients experiencing relapses.
- - A new international Phase II trial is exploring a combination of a therapeutic cancer vaccine (OSE2101) and anti-PD1 (pembrolizumab) as a maintenance therapy for patients with platinum-sensitive recurrences, regardless of prior treatments.
Background: Carboplatin and paclitaxel (CP) have been the standard of care for advanced/recurrent endometrial cancer (EC) for many years. However, this chemotherapy combination shows limited efficacy and recurrences often occur in less than 12 months. ABTL0812 is a novel drug that selectively kill cancer cells by cytotoxic autophagy and has shown anticancer efficacy in preclinical models of EC in combination with CP.
View Article and Find Full Text PDFEndometrioid ovarian cancers (EOvC) are usually managed as serous tumors. In this study, we conducted a comprehensive molecular investigation to uncover the distinct biological characteristics of EOvC. This retrospective multicenter study involved patients from three European centers.
View Article and Find Full Text PDFArticle Synopsis
- - The study aimed to assess the effectiveness of tiragolumab (anti-TIGIT) combined with atezolizumab (anti-PD-L1) as a treatment for PD-L1-positive persistent or recurrent cervical cancer in patients who had already undergone one or two chemotherapy treatments.
- - In a phase II trial involving 171 patients, the combination treatment showed an objective response rate of 19.0%, which was not statistically significant against a predefined historical reference, indicating limited effectiveness.
- - While both treatment groups had low progression-free survival rates (2.8 months for the combination therapy and 1.9 months for atezolizumab alone), the median overall survival was slightly better for the combination group at 11
Background: Breast cancer (BC) incidence increases with age, particularly in HR-positive/HER2-negative subtypes. Cyclin-dependent kinase 4 and 6 inhibitors (CDK 4/6is) alongside endocrine therapy (ET) have emerged as promising treatments for HR-positive/HER2-negative advanced and early BC. However, their efficacy, safety, and impact on quality of life (QoL) in older and frail patients remain underexplored.
View Article and Find Full Text PDFIntercropping and agroforestry systems have been increasingly well studied and documented. Yet, so far, no dataset has provided a systematic synthesis of existing data on intercropping experiments in the specific field of horticulture. A systematic literature search was carried using search terms and applied to Web of Science.
View Article and Find Full Text PDFHeart failure is a chronic condition that affects millions of people worldwide and is associated with high morbidity and mortality. Remote monitoring, which includes the use of non-invasive connected devices, cardiac implantable electronic devices and haemodynamic monitoring systems, has the potential to improve outcomes for patients with heart failure. Despite the conceptual and clinical advantages, there are still limitations in the widespread use of these technologies.
View Article and Find Full Text PDFArticle Synopsis
- Mirvetuximab soravtansine-gynx (MIRV) is an antibody-drug conjugate approved in the U.S. for treating platinum-resistant ovarian cancer, showing promise in a recent phase 3 trial comparing it to standard chemotherapy.
- The study involved 453 participants with high FRα expression, demonstrating that those treated with MIRV had a median progression-free survival of 5.62 months, significantly longer than the 3.98 months for those on chemotherapy.
- Additionally, MIRV led to higher objective response rates (42.3% vs. 15.9%) and longer overall survival (16.46 months vs. 12.75 months), while also resulting in fewer severe
Importance: Mismatch repair deficiency (dMMR) occurs in various cancers, and these tumors are attractive candidates for anti-programmed cell death 1 therapies, such as dostarlimab, a recently approved immune checkpoint inhibitor.
Objective: To assess the antitumor activity and safety of dostarlimab in patients with advanced or recurrent dMMR solid tumors.
Design, Setting, And Participants: The GARNET trial was a phase 1, open-label, single-group, multicenter study that began enrolling May 8, 2017.
Article Synopsis
- In October 2020, dostarlimab, a programmed death-1 inhibitor, was granted early access in France for treating advanced endometrial cancer based on the GARNET trial results and later approved by the European Medicines Agency in April 2021.
- A real-world analysis from November 2020 to June 2021 included data from 87 eligible patients who received at least one dose of dostarlimab, showcasing a disease control rate of 56% and an overall response rate of 35%, aligning with clinical trial findings.
- The study emphasized the urgent need for new treatment options for patients post-platinum in France and noted ongoing research into the efficacy and safety of dostarlim
What Is This Summary About?: Dostarlimab, also known by the brand name JEMPERLI, is a medicine that can be used to treat certain types of endometrial cancer. GARNET is an ongoing phase 1 clinical study that is testing the safety and side effects of dostarlimab and the best way to administer it to patients. The results presented in this summary are from a time point in the middle of the study.
View Article and Find Full Text PDFPurpose: This interim report of the GARNET phase I trial presents efficacy and safety of dostarlimab in patients with advanced or recurrent endometrial cancer (EC), with an analysis of tumor biomarkers as prognostic indicators.
Patients And Methods: A total of 153 patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) and 161 patients with mismatch repair proficient (MMRp)/microsatellite stable (MSS) EC were enrolled and dosed. Patients received 500 mg dostarlimab every 3 weeks for four cycles, then 1,000 mg every 6 weeks until progression.
Background: Uterine clear cell carcinomas (CCC) represent less than 5% of uterine cancers. Their biological characteristics and clinical management remain uncertain. A multicenter study to explore both clinical and molecular features of these rare tumors was conducted.
View Article and Find Full Text PDF